CALCILYTIX THERAPEUTICS

calcilytix-therapeutics-logo

Calcilytix is investigating encaleret, a small molecule antagonist of the CaSR, as a potential therapeutic for hypoparathyroidism and ADH1. The CaSR is a G-protein-coupled receptor for which extracellular calcium is the primary ligand. The major physiologic role of the CaSR is to function conceptually as a ‘calciostat’ and maintain serum calcium levels by regulating the release of PTH and calcium reabsorption.

#SimilarOrganizations #Website #More

CALCILYTIX THERAPEUTICS

Social Links:

Industry:
Health Care

Founded:
2015-01-01

Address:
San Francisco, California, United States

Country:
United States

Website Url:
http://www.calcilytix.com

Total Employee:
11+

Status:
Active

Email Addresses:
[email protected]


Similar Organizations

context-therapeutics-logo

Context Therapeutics

Context Therapeutics is a clinical-stage biopharmaceutical company.

Official Site Inspections

http://www.calcilytix.com Semrush global rank: 4.43 M Semrush visits lastest month: 2.49 K

  • Host name: 141.193.213.11
  • IP address: 141.193.213.11
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Calcilytix Therapeutics"

Calcilytix Therapeutics, Inc. - Drug pipelines, Patents, Clinical ...

Explore Calcilytix Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 5 clinical trials, and 3 literature, Disease Domain:Endocrinology and Metabolic Disease, …See details»

Meet Our Partners | HypoPARAthyroidism Association

Bridgebio/Calcilytix. Calcilytix Therapeutics is a clinical-stage biopharmaceutical company based in California, USA. We are an affiliate of BridgeBio Pharma, whose goal is to create life …See details»

Calcilytix - Overview, News & Similar companies | ZoomInfo.com

Who is Calcilytix. Calcilytix Therapeutics, an affiliate of BridgeBio Pharma, is a clinical-stage biopharmaceutical company focused on developing a targeted therapy f or disorders of …See details»

Bridgebio/Calcilytix :: HypoPARAthyroidism Association Inc.

Calcilytix is investigating Encaleret as a potential treatment for ADH1 (autosomal dominant hypocalcemia type 1), a genetic cause of hypoPARAthyroidism. Encaleret is an …See details»

Calcilytix Therapeutics - Contacts, Employees, Board Members, …

Calcilytix is a clinical-stage biopharmaceutical company. Start Free Trial . Chrome ExtensionSee details»

what is autosomal dominant hypocalcemia type 1? - BridgeBio

What is autosomal dominant hypocalcemia type 1?. Autosomal dominant hypocalcemia type 1 (ADH1) is a common form of genetic hypoparathyroidism. Gain-of-function variants in the …See details»

FDA Fast Track Designation for Encaleret | BridgeBio

Jun 1, 2021 “Balancing near-normal blood and avoiding excess urinary calcium is a daily struggle for patients with ADH1 as the range of symptoms produced by the highs and lows of …See details»

Calcilytix Therapeutics - VentureRadar

Calcilytix is investigating encaleret, a small molecule antagonist of the CaSR, as a potential therapeutic for hypoparathyroidism and ADH1.See details»

Director/Sr. Director, Regulatory Affairs | San Francisco, CA/Hybrid

Apply Now. About Calcilytix & BridgeBio Pharma. Calcilytix Therapeutics, an affiliate of BridgeBio Pharma, is developing encaleret (CLTX-305), a negative allosteric modulator of the calcium …See details»

Calcilytix DetectHypopara Sponsored Testing Program

In partnership with Calcilytix Therapeutics (a BridgeBio Company), this DetectHypoparaâ„¢ Genetic Testing Program provides US and Canada physicians with access to no-cost genetic …See details»

Calcilytix - Genome Medical

Calcilytix Therapeutics and Genome Medical are here to help you through your genetics journey. Calcilytix Therapeutics (a BridgeBio Company) has partnered with Genome Medical to provide …See details»

Efficacy and Safety of Encaleret in Autosomal Dominant …

Sep 27, 2023 Supported by a public–private partnership between the Division of Intramural Research, National Institute of Dental and Craniofacial Research, National Institutes of Health, …See details»

BridgeBio Pharma’s Calcilytix Therapeutics Initiates Phase 2 Study …

Sep 21, 2020 * Topline proof-of-concept results in ADH1 anticipated in 2021 * Currently, there are no approved therapies for ADH1PALO ALTO, Calif., Sept. 21, 2020 (GLOBE NEWSWIRE) …See details»

Calcilytix Therapeutics | Encaleret Phase 2 Study | BridgeBio

Sep 21, 2020 Palo Alto, Calif., September 21, 2020 — BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate Calcilytix Therapeutics, Inc. announced today the initiation of a Phase 2 single-center …See details»

BridgeBio's Calcilytix Sees POC For Encaleret And Options To

Mar 23, 2021 Calcilytix chief medical officer Jonathan Fox talked to Scrip about the development plans for encaleret for the rare form of hypoparathyroidism. BridgeBio presented Phase IIb …See details»

BridgeBio Pharma’s Calcilytix Therapeutics Initiates Phase 2

Sep 21, 2020 --BridgeBio Pharma, Inc. affiliate Calcilytix Therapeutics, Inc. announced today the initiation of a Phase 2 single-center study of encaleret in individuals with ADH1 conducted at …See details»

Encaleret(CLTX-305) Normalizes Mineral Homeostasis Parameters …

And BridgeBio affiliate Calcilytix Therapeutics, Inc. In patients with ADH1, encaleret administered twice daily rapidly corrected and maintained mineral homeostasis within the normal range, as …See details»

AHA Phase 3 Design Poster vF - BridgeBio

BridgeBio Pharma, Inc. affiliate Calcilytix Therapeutics, Inc, San Francisco, CA, USA, 94104 Study Number: CLTX-305-201; ClinicalTrials.gov Identifier: NCT04581629 Background Period …See details»

HypoPARAthyroidism Association, Inc.

Oct 2, 2024 One of the most exciting things in my most recent research is finding your organization. Literally seeing a bunch of people on video who had hypoPARA. Coming from a …See details»

linkstock.net © 2022. All rights reserved